Atai life sciences announces initiation of phase 1 proof-of-concept clinical trial for its sol-gel based direct-to-brain drug delivery technology

– atai has initiated a phase 1 proof-of-concept clinical trial to demonstrate the safety, tolerability, and direct-to-brain delivery of intranasal inb-01, a sol-gel based drug-delivery technology.

ATAI Ratings Summary

ATAI Quant Ranking